## Abstract ## Objective Current treatment options for psoriatic arthritis (PsA) are limited. Leflunomide, an oral pyrimidine synthesis inhibitor, is highly effective in the treatment of rheumatoid arthritis, and small studies have suggested similar efficacy in PsA. We undertook this double‐blind,
Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression
✍ Scribed by Philip J. Mease; Alan J. Kivitz; Francis X. Burch; Evan L. Siegel; Stanley B. Cohen; Peter Ory; David Salonen; Joel Rubenstein; John T. Sharp; Wayne Tsuji
- Publisher
- John Wiley and Sons
- Year
- 2004
- Tongue
- English
- Weight
- 109 KB
- Volume
- 50
- Category
- Article
- ISSN
- 0004-3591
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract ## Objective To investigate in a randomized clinical trial setting with an aggressive combination‐therapy arm and a mild‐monotherapy arm, whether therapy‐induced changes in urinary C‐terminal crosslinking telopeptide of type I collagen (CTX‐I) and type II collagen (CTX‐II) predict 5‐ye
## Abstract ## Objective To investigate whether there are differential effects of disease activity and damage on physical functioning as measured by the Health Assessment Questionnaire (HAQ) over the course of psoriatic arthritis (PsA). ## Methods Between June 1993 and March 2005, 382 patients a